



For Immediate Release – June 14, 2011

Contact: Chuck Oehler, 608-441-8334

Primorigen Biosciences, Inc. Announces Exclusive Distribution Partnership with STEMCELL Technologies, Inc.

Madison, WI. Primorigen Biosciences, Inc. has entered into an exclusive worldwide distribution agreement with STEMCELL Technologies, Inc., of Vancouver, British Columbia, Canada. The agreement covers distribution of StemAdhere(TM), a new cell adhesion product developed and manufactured by Primorigen that promotes stem cell growth and pluripotency—the ability to become any cell type. The product is designed as a tool to help researchers focused on reversing conditions such as diabetes, Alzheimer’s Disease and other degenerative diseases.

Under the agreement, StemAdhere™ will be sold by STEMCELL Technologies under Primorigen’s Brand. Primorigen will continue to produce StemAdhere™ in its Madison, WI facilities, and STEMCELL Technologies will use its global sales network and market leadership in stem cell culture media to promote StemAdhere™ worldwide. STEMCELL Technologies will provide customer technical support, and both firms will cooperate on joint marketing efforts.

StemAdhere™ has received a positive response from major academic and industrial customers and is a highly complementary product with STEMCELL Technologies’ market-leading mTeSR®1 and TeSR™2 stem cell culturing media. As a defined substrate for maintaining human pluripotent stem cell in their undifferentiated state, StemAdhere™ reduces variability of experimental results, and eliminates cumbersome steps required for other matrices, addressing two key market needs.

“STEMCELL Technologies is actively working on providing the most comprehensive and defined set of products for research involving human pluripotent stem cells. The addition of StemAdhere(TM) to our product portfolio further extends our market-leading position in this area,” said Dr. Clive Glover, head of product management at STEMCELL Technologies.

“We are pleased with the growing demand for StemAdhere™, said Chuck Oehler, CEO of Primorigen Biosciences. “Partnering with STEMCELL Technologies will enable us to accelerate market awareness of this valuable product and serve more customers in less time.”

STEMCELL Technologies Inc is a privately-owned biotechnology company that develops specialty cell culture media, cell separation products and ancillary reagents for life science research. Widely recognized as an international market leader in stem cell culture technologies, STEMCELL delivers over 1000 products to more than 70 countries worldwide.

Primorigen Biosciences, Inc., is an emerging leader in developing innovative solutions for stem cell maintenance, proliferation, characterization and assay development. The company also is developing human stem cell-derived disease models for high throughput, low cost compound and toxicity screening, addressing a strong need in pharmaceutical drug discovery.